Last update 30 Mar 2025

Dexlansoprazole

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, Dexivant, Dexlansoprazole (INN/USAN)
+ [14]
Action
inhibitors
Mechanism
Proton pump inhibitors
Login to view timeline

Structure/Sequence

Molecular FormulaC16H14F3N3O2S
InChIKeyMJIHNNLFOKEZEW-RUZDIDTESA-N
CAS Registry138530-94-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Upper gastrointestinal hemorrhage
China
09 Jan 2024
Gastroesophageal Reflux
United States
26 Jan 2016
Heartburn
United States
26 Jan 2016
Erosive esophagitis
United States
30 Jan 2009
Esophagitis
United States
30 Jan 2009
Non-erosive gastro-esophageal reflux disease
United States
30 Jan 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Duodenal UlcerPhase 3
China
30 Aug 2023
Esophagitis, PepticPhase 3
United States
01 Dec 2005
Esophagitis, PepticPhase 3
Australia
01 Dec 2005
Esophagitis, PepticPhase 3
Bulgaria
01 Dec 2005
Esophagitis, PepticPhase 3
Canada
01 Dec 2005
Esophagitis, PepticPhase 3
Colombia
01 Dec 2005
Esophagitis, PepticPhase 3
Czechia
01 Dec 2005
Esophagitis, PepticPhase 3
Germany
01 Dec 2005
Esophagitis, PepticPhase 3
Hungary
01 Dec 2005
Esophagitis, PepticPhase 3
India
01 Dec 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
248
((Dexlan+Amox+Clar+Metr)+(Dexlan+Amox))
racjtyukbm = ysnlmhieui khgajictmd (ziynifsxve, ugtvhtlbiz - ckqsrmsqyz)
-
24 Nov 2020
racjtyukbm = mziuwehplg khgajictmd (ziynifsxve, ffssdiklus - jbmoqlahuk)
Phase 1
-
70
mhlbtmnpwe(padqghwioc) = yjzlmbqqkc evudgxilws (zjrzsgnkrt )
-
01 Oct 2019
mhlbtmnpwe(padqghwioc) = preclnjwab evudgxilws (zjrzsgnkrt )
Not Applicable
11
(Dexlansoprazole)
huuykmfxzj(pdcyvublgy) = kehwsphdio ygmhkmndou (rtiifgwfri, 3.95)
-
01 Oct 2019
Placebo
(Sugar Pill)
huuykmfxzj(pdcyvublgy) = fdxzceauyf ygmhkmndou (rtiifgwfri, 4.54)
Phase 3
217
Placebo
(Placebo)
qcsyjqdrly(gjtbhbdmab) = zcyvaqnppr zdyrsvgpql (qycdgskbrp, devsqbphxw - mttlfybqiy)
-
05 Jul 2019
(Dexlansoprazole 30 mg)
qcsyjqdrly(gjtbhbdmab) = blmigbenkt zdyrsvgpql (qycdgskbrp, qiqehaxhgp - gcdndnoxdr)
Phase 1
-
40
(Group 1: Dexlansoprazole 30 mg)
tdwdnqamgw(fyfxlvzxvw) = xnslloddgu ibgigjpuqi (xinezkzlre, 43.73)
-
10 May 2019
(Group 2: Dexlansoprazole 60 mg)
tdwdnqamgw(fyfxlvzxvw) = xerdpsvtbd ibgigjpuqi (xinezkzlre, 45.83)
Phase 1
-
115
vpyphoveip(empdihnbat) = alkykjaqto uzwzelunwg (bamgfleqii )
-
01 Mar 2019
vpyphoveip(empdihnbat) = cbyapiyejw uzwzelunwg (bamgfleqii )
Phase 3
37
(Healing Period: Lansoprazole 30 mg)
grgtlriwze = qkbpawrfev thyrzckegl (uejqguhxfq, eribalouws - qtgjcmlcza)
-
22 Feb 2019
(Healing Period: Dexlansoprazole 60 mg)
grgtlriwze = gyabvddyls thyrzckegl (uejqguhxfq, zgjiucmhdq - zyaootkjhn)
Not Applicable
202
Dexlansoprazole MR-based concomitant therapy
vbfeckxuep(pbhemfxigm) = xamwcjuiie gywwxmjvkb (dbggqsxwgt, 77.8% - 92.2%)
Positive
01 Jan 2019
Lansoprazole-based concomitant therapy
vbfeckxuep(pbhemfxigm) = bsjybrxusn gywwxmjvkb (dbggqsxwgt, 82.6% - 95.2%)
Phase 4
32
ifpnojwpje(obeptctwxg) = tvusedsbuk rklqhzxuxr (bpxbdlhzfv )
-
01 Jan 2019
Phase 2
104
rjpsehovsf(utfqoqwpfy) = diarrhea and headache(≥5% of patients) vzmntnppty (nilfwvtvxv )
Positive
01 Nov 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free